We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

117 hedge funds and large institutions have $938M invested in Coherus Oncology in 2019 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more call options, than puts

Call options by funds: $1.18M | Put options by funds: $358K

58% more capital invested

Capital invested by funds: $595M → $938M (+$343M)

35% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 31

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

5% more funds holding

Funds holding: 111 → 117 (+6)

2.69% more ownership

Funds ownership: 96.6% → 99.29% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
117
Holders Change
+6
Holders Change %
+5.41%
% of All Funds
2.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
23
Increased
42
Reduced
31
Closed
17
Calls
$1.18M
Puts
$358K
Net Calls
+$825K
Net Calls Change
+$1.13M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$13.5M
2
PHS
PFM Health Sciences
California
+$12.6M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.2M
4
TCIM
TIAA CREF Investment Management
New York
+$12.1M
5
Millennium Management
Millennium Management
New York
+$9.96M

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$18.4M
2
CC
Carlson Capital
Texas
-$16.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.04M
4
State Street
State Street
Massachusetts
-$5.57M
5
RCMNY
Rubric Capital Management (New York)
New York
-$5.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
51
Credit Suisse
Switzerland
$2.49M -$71.7K -5,376 -3%
HCMT
52
Highland Capital Management (Texas)
Texas
$2.44M -$680K -51,000 -22%
PVI
53
Pura Vida Investments
New York
$2.26M -$607K -45,458 -22%
EP
54
Eversept Partners
New York
$1.64M +$1.6M +120,036 New
ARTA
55
A.R.T. Advisors
New York
$1.4M +$1.37M +102,943 New
Citigroup
56
Citigroup
New York
$1.3M -$335K -25,136 -21%
Jacobs Levy Equity Management
57
Jacobs Levy Equity Management
New Jersey
$1.29M +$588K +44,100 +87%
Rafferty Asset Management
58
Rafferty Asset Management
New York
$1.25M +$1.22M +91,262 New
RhumbLine Advisers
59
RhumbLine Advisers
Massachusetts
$1.22M +$282K +21,164 +31%
Swiss National Bank
60
Swiss National Bank
Switzerland
$1.1M +$34.7K +2,600 +3%
California State Teachers Retirement System (CalSTRS)
61
California State Teachers Retirement System (CalSTRS)
California
$1.09M -$24K -1,799 -2%
SFM
62
Sphera Funds Management
Israel
$1.03M +$1.01M +75,600 New
Squarepoint
63
Squarepoint
New York
$1.03M +$1.01M +75,389 New
AllianceBernstein
64
AllianceBernstein
Tennessee
$971K – – –
State of Wisconsin Investment Board
65
State of Wisconsin Investment Board
Wisconsin
$948K +$212K +15,900 +30%
BA
66
Boston Advisors
Massachusetts
$807K +$348K +26,105 +79%
AAP
67
Ardsley Advisory Partners
Connecticut
$682K +$467K +35,000 +233%
New York State Common Retirement Fund
68
New York State Common Retirement Fund
New York
$675K – – –
Two Sigma Investments
69
Two Sigma Investments
New York
$575K -$2.56M -191,958 -82%
Morgan Stanley
70
Morgan Stanley
New York
$570K -$551K -41,329 -50%
DMK
71
David M. Knott
$552K +$1.33K +100 +0.2%
Two Sigma Advisers
72
Two Sigma Advisers
New York
$550K +$119K +8,900 +28%
ECM
73
ExodusPoint Capital Management
New York
$506K +$494K +37,062 New
Manulife (Manufacturers Life Insurance)
74
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$471K +$29.2K +2,186 +7%
AIG
75
American International Group
New York
$452K -$14.3K -1,072 -3%
1 2
3
4 5

CHRS Hedge Fund Activity: Q1 2019 in Review

117 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2019, worth a combined $938M — up 58% from $595M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CHRS positions and 17 closed out — a net gain of 6 holders — while 42 added to existing stakes and 31 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $13.5M. The largest seller was Deutsche Bank, cutting an estimated $18.4M.

  • 117 institutional investors held Coherus Oncology (CHRS) as of Q1 2019, up from 111 in Q4 2018.
  • Funds reported $938M of Coherus Oncology stock for Q1 2019, up 58% quarter-over-quarter.
  • 23 funds opened new Coherus Oncology positions in Q1 2019 and 17 closed out, a net change of +6 holders.
  • The largest Coherus Oncology buyer in Q1 2019 was JP Morgan Chase, an estimated $13.5M added.
  • The largest Coherus Oncology seller in Q1 2019 was Deutsche Bank, an estimated $18.4M sold.

Based on aggregated 13F filings for Q1 2019.